-
Pantoprazole Sodium for Injection, a wholly-owned subsidiary of Sialon Pharmaceuticals, passed the consistency evaluation of generic drugs
Time of Update: 2021-11-05
On September 8, Sialon Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Hunan Sialon Pharmaceutical, had recently obtained the "Approval Notice for Supplementary Drug Ap
-
Takeda China supports the 4th National Gastroesophageal Reflux Disease Awareness Week
Time of Update: 2021-11-05
Lu Zhaofeng, Executive Vice President of the China Association for the Promotion of International Health Care, said: "Since the launch of the National Gastroesophageal Reflux Disease Awareness Week in 2018, we have carried out various forms of disease science education, and we have been working hard to improve disease awareness and attention.
-
Deqi Pharmaceutical Celiniso Phase II clinical trial application approved in China for the treatment of myelofibrosis
Time of Update: 2021-11-05
According to the National Comprehensive Cancer Network (NCCN) guidelines, intermediate-risk-2 and high-risk patients who are not suitable for allogeneic hematopoietic stem cell transplantation can receive JAK inhibitor ruxolitinib or if the platelet count is ≥50×109/L fedratinib treatment (NCCN, 2020) .
-
The current dilemma of new drug research and development-the multi-dimensional use of big data and artificial intelligence
Time of Update: 2021-11-05
Xu mentioned that the "AI+Pharmaceutical" model has become an important breakthrough in shortening the drug development process , The addition of AI intelligence and big data technology may change the new drug research and development model, improve research and development efficiency and reduce research and development costs, open a new situation for new drug research and development, and even usher in the outbreak of the biomedical industry .
-
New formulation of Pfizer JAK inhibitor approved in China to treat rheumatoid arthritis
Time of Update: 2021-11-05
Text|Pharmaceutical Mission HillsOn September 13, Pfizer announced that the National Medical Products Administration (NMPA) of China has officially approved the marketing application of its oral JAK inhibitor tofacitib citrate sustained-release tablets for insufficient efficacy against methotrexate Or adult patients with moderate to severe active rheumatoid arthritis (RA) who cannot tolerate it can be used in combination with methotrexate or other non-biological disease-improving anti-rheumatic drugs (DMARD) .
-
Biopharmaceutical company Oculis announces establishment of Hong Kong office and appointment of global chief medical officer
Time of Update: 2021-11-05
Ruyu Chang will play an important role in the executive management team, strengthen Oculis' existing businesses in China, Europe and the United States, and help the company's global development .
-
Glipizide tablets, a wholly-owned subsidiary of Zhongsheng Pharmaceutical, passed the consistency evaluation of generic drugs
Time of Update: 2021-11-05
There are three main types of oral hypoglycemic drugs in clinical use.
According to the chemical drug terminal competition pattern database of Chinese city public hospitals on Mynet, the sales of glipizide tablets from 2018 to 2020 are RMB 222.
-
Nuocheng Jianhua brings the second-generation pan-TRK inhibitor ICP-723 to the Zhongguancun Forum 2021 for the first time
Time of Update: 2021-11-05
Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) will bring the company's self-developed second-generation pan-TRK small molecule inhibitor ICP-723 for the first time at Zhongguancun Forum 2021, and will participate in international technology transactions at the forum Conference "New Technology and New Products First Launch and Promotion Conference" .
-
Ou Tangjing(R) (Engligliflozin Tablets) new indication for adult patients with heart failure with preserved ejection fraction has submitted an application for registration in China
Time of Update: 2021-11-05
Shanghai, October 11, 2021/PRNewswire/ - On September 30, 2021, Boehringer Ingelheim-Eli Lilly jointly announced that it has formally submitted its Diabetes Alliance's SGLT2 to the China National Medical Products Administration Center for Drug Evaluation Inhibitor Otangjing® (generic name: Enpagliflozin tablets) is used for the registration application of new indications for adult patients with heart failure with preserved ejection fraction .
-
The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O drug by Kaixing Pharmaceutical was approved in China
Time of Update: 2021-11-05
HK, hereinafter referred to as "Development Pharmaceutical") is pleased to announce that ALK-1 monoclonal antibody (GT90001C) is combined with Nivolumab The clinical trial was approved by the National Medical Products Administration (NMPA) of China on October 9 for patients with advanced hepatocellular carcinoma (HCC) who have not been systematically treated .
-
Merck’s “New Crown Medicine” submitted its listing application for the third climax in the anti-infective field?
Time of Update: 2021-11-05
S. Food and Drug Administration (FDA) for an emergency use authorization (EUA) of Molnupiravir for the treatment of mild to moderate COVID-19 that has developed a severe risk and/or hospitalization risk Adult patients with pneumonia .
-
Luye Pharma's goserelin microsphere preparation for the treatment of stage III prostate cancer reaches the preset end point
Time of Update: 2021-11-05
The Phase III clinical trial of LY01005 is a randomized, open, positive drug-controlled clinical study to evaluate the effectiveness and safety of continuous intramuscular injection of LY01005 in the treatment of prostate cancer patients .
-
CureVac abandons the development of the first-generation COVID-19 vaccine
Time of Update: 2021-11-05
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn October 12, the German company CureVac announced that the development of the COVID-19 vaccine will focus on the development of the second-generation mRNA candidate vaccine in cooperation with GSK, and its first-generation COVID-19 candidate vaccine CVnCoV will be obtained from the European Medicines Agency ( EMA) withdrawn in the current approval process .
-
Novavax will participate in the European World Vaccine Conference
Time of Update: 2021-11-05
date: Wednesday, October 20, 2021 time: 11:30 am – 12:00 pm Central European Time (CET) / 5:30–6:00 pm Eastern Daylight Time (EDT) title: Novavax NanoFlu vaccine and new coronary pneumonia NanoFlu vaccine development update Novavax participants: Vivek Shinde, MD, Vice President of Clinical Development date: Wednesday, October 20, 2021 date:
-
Bayer Supports Health Science Lectures Entering Guangzhou Jishan Community
Time of Update: 2021-11-05
The "Healthy China Action·Health Science Popularization Community Action" public welfare lecture will be held on October 14 Walked into Jishan Community in Tianhe District, Guangzhou City, and brought health knowledge lectures with the theme of "Improving Immunity and Protecting Health" .
-
Will there be a "cut-off" incident in the centralized procurement of Chinese patent medicines?
Time of Update: 2021-11-05
So, as a manufacturing company, if the centralized procurement wins the bid, in order to prevent the price of raw materials from rising, can it choose to reserve a large amount of medicinal materials for emergency needs?Of course this is fine!However, the current initial goal of the relevant government departments to prepare for centralized procurement is to work on the "large quantities and high prices" of proprietary Chinese medicine products .
-
A large number of pharmacies apply for the "Internet Drug Information Service Qualification Certificate" to prepare for online drug sales
Time of Update: 2021-11-05
Proof of providing Internet drug servicesProof of providing Internet drug servicesRecently, the Hebei Provincial Food and Drug Administration issued an announcement that according to the relevant provisions of the "Internet Drug Information Service Management Measures", after review, Hebei Haishengtang Pharmacy Chain Co.
-
Amlodipine benzoate dry suspension, a wholly-owned subsidiary of Poinsettia, obtained the notification of drug clinical trial
Time of Update: 2021-11-05
On September 14, Poinsettia issued an announcement stating that its wholly-owned subsidiary, Poinsettia Pharmaceuticals, declared that the dry suspension of amlodipine benzoate (acceptance number: CXH
-
TOP14 R&D efficiency PK of pharmaceutical companies: Who is more efficient in independent R&D vs. external innovation?
Time of Update: 2021-11-05
However, the difference is that most of the R&D output of Novartis and GlaxoSmithKline comes from patent research projects, while the R&D output of Pfizer, Merck and Gilead is more derived from mergers and acquisitions and licensing .
-
The national drug counter is here!
Time of Update: 2021-11-05
One week after pharmacies set up the "National Central Procurement Drug Sales Counter", the number of drugs sold increased by 46% on average, and the highest increase was 80% .
